On September 18th, Solx Inc. , a Boston-based spinout from Boston University's Photonics Center, now based in Waltham, MA, announced that it had received FDA 510(k) clearance for its SOLX 790 Titanium:Sapphire laser to perform laser trabeculoplasty (TLT). The clearance was based on the results of a multicenter, international clinical trial that established equivalency of TLT to argon laser trabeculoplasty (ALT) in its ability to reduce IOP in patients who have primary open-angle glaucoma and have poorly controlled IOP on maximally tolerated medications, and/or who have prior failed trabeculoplasty. The laser was previously approved for sale in Europe and Canada. In the trial, which was conducted across the United States, Europe, Canada and Israel, more than 180 patients were randomized either for ALT or TLT. Results showed that patients at 12-month follow-up achieved a mean IOP reduction of 6.8 ± 4.7 mmHg (25.8 percent) for TLT vs. 5.7 ± 4.8 mmHg (22.2 percent) for ALT. "Patie...